Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03535935
Other study ID # RE-02
Secondary ID
Status Recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date July 1, 2018
Est. completion date December 31, 2022

Study information

Verified date December 2020
Source The University of Hong Kong
Contact Sydney CW TANG, MD, PhD
Phone +852 22553879
Email scwtang@hku.hk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This add-on open-label randomised controlled pragmatic trial aims to: 1. evaluate the effect of add-on astragalus treatment on type 2 diabetic patients with stage 2 to 3 chronic kidney disease and macroalbuminuria. 2. estimate treatment effect, variance, recruitment rate, attrition rate and change in clinical manifestation including Chinese medicine syndrome for parameters optimisation and feasibility assessment for a subsequent phase III randomised controlled trial. 3. assess response predictors for efficacy and safety among type 2 diabetic patients with stage 2 to 3 chronic kidney disease and macroalbuminuria receiving add-on astragalus treatment


Description:

This add-on open-label randomised controlled pragmatic trial. Sample size is calculated based on planned regression analysis. We believe an annual GFR benefit of 5 ml/min/1.73m2 is deemed significant clinically. 118 patients are therefore needed to offer a power of 70% to detect a GFR difference of 5 ml/min/1.73m2 over 48-week allowing 15% attrition rate for this study with a significance level of alpha equals to 0.05. A trial management committee (TMC) formed by PA, Co-As and RA will centralise all the data of the trial. Co-As and RA will collect, clean and send the data of patients to TMC on a weekly basis. All data will be double entered to computer and cleaned before analysis to prevent data entry errors. All data transfer will be encrypted to protect patients' confidentiality. TMC will have regular meetings monthly with experts to discuss the progress of the trial. An independent Data Monitoring Board (DMB) will be invited to monitor the progress of the trial. DMB will advise ethics committee to terminate the trial if data is showing extreme benefits or harm. Detailed guidelines will be discussed and set by DMB. Missing values will be imputed with last observation carried forward. Patient without a postrandomisation assessment for a particular efficacy endpoint will be excluded from the analysis of that endpoint. Regression analysis will be used to compare the adjusted mean of eGFR, UACR, HbA1c, FBG, and other biomarkers at week 48 between groups and statistical significance. The adverse events will be analysed in a narrative manner. The percentage of all adverse events and the rate of attrition due to adverse events will be compared between intervention groups and control groups. To minimise Type I error inflation, the analysis will follow a hierarchical approach in the order of 1) comparison of baseline to end of treatment on eGFR and UACR; 2) comparison of baseline to end of treatment on other outcome measurements; 3) comparison of baseline to treatment midpoints on eGFR and UACR and 4) comparison of baseline to treatment midpoints on other outcome measurements. Subgroup analysis will be performed for different age groups, gender chronic kidney disease stage and severity of albuminuria. The dependent variable is the treatment response which is categorised into: 1. Improved or stabilised renal function, defined as eGFR after 48-week treatment being higher or equal to baseline. 2. Non-responder, defined as patients having eGFR decreased at a rate of less than 5 mL/min/1.73m2 after 48-week treatment compared to baseline. 3. Rapid deteriorating renal function, defined as eGFR of more than 5 mL/min/1.73m2 after 48-week treatment compared to baseline. Potential prognostic variables (baseline values) include: 1. Demographics and past medical history: Age, gender, body mass index (BMI), systolic blood pressure, history and duration of smoking and alcohol consumption and others 2. Chinese medicine diagnosis: presence of Chinese medicine syndromes (e.g. spleen and kidney qi deficiency) based on the presentation of standardised and commonly documented signs and symptoms 3. Biochemical profile


Recruitment information / eligibility

Status Recruiting
Enrollment 118
Est. completion date December 31, 2022
Est. primary completion date June 30, 2022
Accepts healthy volunteers No
Gender All
Age group 35 Years to 80 Years
Eligibility Inclusion Criteria: - diagnosed with type 2 diabetes for at least 5 years; - with an estimated glomerular filtration rate (GFR) =30 ?90 mL/min/1.73m2 confirmed with repeat testing over three or more months calculated by the abbreviated MDRD study equation; - persistent macroalbuminuria with spot urine albumin-to-creatinine ratio (UACR) = 300 mg/g confirmed by at least 2 out of 3 consecutive first morning void urine samples; - on stable dose of anti-diabetic drug including insulin for 12 weeks; - on stable dose of angiotensin-converting-enzyme inhibitor or angiotensin receptor blocker for 12 weeks; and - willing and able to give written informed consent Exclusion Criteria: - with known history of glomerulonephritis, polycystic kidney disease, systemic lupus erythematosus, any suggestive evidence of nondiabetic glomerulopathy; - with known history of kidney transplant; - with concurrent severe disorders of heart, brain, liver, and hematopoietic system, tumor and mental disorder; - with deranged liver function; - poorly controlled blood pressure; - with known history of intolerance or malabsorption of oral medications; - with uncontrollable urinary infection; - experiencing pregnancy; or - participating in other clinical trial within 30 days

Study Design


Intervention

Drug:
Astragalus Powder
3 grams of water soluble astragalus sachets (equivalent to 15g raw herbs) administrated orally on top of standard medical care for 48 weeks. Patients will have 5 days of medicine per week and will be advised to take the medicine once daily dissolved in boiling water in the first 5 days of the week.
Other:
Routine medical care (active comparator)
Angiotensin converting enzyme inhibitor or angiotensin receptor blocker

Locations

Country Name City State
Hong Kong Queen Mary Hospital Hong Kong
Hong Kong School of Chinese Medicine Hong Kong

Sponsors (2)

Lead Sponsor Collaborator
The University of Hong Kong School of Chinese Medicine, The University of Hong Kong

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in biomarkers related to inflammation and fibrosis From baseline to 48 weeks after treatment
Primary Change in estimated GFR Efficacy and safety From baseline to 48 weeks after treatment
Primary Change in spot urine albumin-to-creatinine ratio Efficacy and safety From baseline to 48 weeks after treatment
Secondary Change in glycated haemoglobin (HbA1c) From baseline to 48 weeks after treatment
Secondary Change in urinary monocyte chemotactic protein 1 (MCP-1) From baseline to 48 weeks after treatment
Secondary Change in urinary Cystatin C From baseline to 48 weeks after treatment
Secondary Change in lipids From baseline to 48 weeks after treatment
See also
  Status Clinical Trial Phase
Recruiting NCT06006689 - Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Diabetic Kidney Disease (Syndrome of Qi Deficiency With Blood Stasis) Phase 2
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT05086549 - An Observation Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With DKD and Proteinuria
Recruiting NCT05008276 - Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Completed NCT02276196 - Effect of LIXIsenatide on the Renal System Phase 4
Not yet recruiting NCT06120569 - Evaluate the Role of Soleus Muscle Exercise in Glycaemic Control in Diabetic Kidney Disease Patients N/A
Completed NCT02545049 - Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease Phase 3
Active, not recruiting NCT02237352 - Mechanisms of Diabetic Nephropathy in Ecuador
Active, not recruiting NCT06176599 - Clinical Study on the Treatment of Diabetic Kidney Disease With Shenxiao Yuning Decoction With Syndrome of Qi and Yin Deficiency and Blood Stasis N/A
Recruiting NCT03716401 - Prognostic Imaging Biomarkers for Diabetic Kidney Disease
Terminated NCT03840343 - Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease Phase 1
Completed NCT01377688 - Personalized Diabetic Kidney Disease Risk Info to Initiate and Maintain Health Behavior Changes N/A
Active, not recruiting NCT05514548 - Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease Phase 2
Recruiting NCT05507892 - Renal Mechanism of SGLT2 Inhibition Phase 2
Not yet recruiting NCT06049550 - The Influence of the Thickening of Bowman's Capsule on the Clinical Prognosis of Patients With Diabetic Kidney Disease
Not yet recruiting NCT05514184 - Plant-Focused Nutrition in Patients With Diabetes and Chronic Kidney Disease N/A
Active, not recruiting NCT04589351 - Kidney Fat in Type 2 Diabetes and the Effects of Ezetimibe Phase 3
Active, not recruiting NCT04531163 - Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy Phase 2/Phase 3
Active, not recruiting NCT03620773 - Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes Phase 1/Phase 2
Suspended NCT01878045 - Mechanisms of Diabetic Kidney Disease in American Indians